Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient

Di Biagio, Antonio; Rosso, Raffaella; Siccardi, Marco; D'Avolio, Antonio; Bonora, Stefano; Viscoli, Claudio
October 2009
Journal of Antimicrobial Chemotherapy (JAC);Oct2009, Vol. 64 Issue 4, p874
Academic Journal
The article presents a study that deals with co-administration of raltegravir and cyclosporin in an HIV-infected subject. Focal to the study was the interaction between raltegravir and cyclosporin in middle-aged Caucasian male hemophiliac with HIV-1 suffered from hepatitis C virus (HCV)-related end-stage liver disease, HCV genotype 1A. Based on their findings, the authors suggested the switch from an injectable to an oral medication. They recommended co-administration of raltegravir and cyclosporin without dose adjustments.


Related Articles

  • Lateral rectus muscle paralysis induced by ribavirin and pegylated interferon-α2a in a patient with HIV/HCV co-infection. Mellon, Guillaume; Stitou, Hind; Aoun, Olivier; Tubiana, Roland; Thibault, Vincent; Valantin, Marc; Bricaire, François // Journal of Infection & Chemotherapy;Dec2012, Vol. 18 Issue 6, p937 

    We report a lateral rectus muscle paralysis occurring 2 weeks after initiation of an interferon-α and ribavirin treatment in a patient with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) virus co-infection. This patient presented with horizontal diplopia that appeared rapidly...

  • Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Macías, J.; Girón-González, J. A.; González-Serrano, M.; Merino, D.; Cano, P.; Mira, J. A.; Arizcorreta-Yarza, A.; Ruíz-Morales, J.; Lomas-Cabeza, J. M.; García-García, J. A.; Corzo, J. E.; Pineda, J. A. // Gut;Mar2006, Vol. 55 Issue 3, p409 

    Background: Liver biopsy is an invasive technique with associated major complications. There is no information on the validity of five non-invasive indexes based on routinely available parameters, estimated and validated in hepatitis C virus (HCV) monoinfected patients, in human immunodeficiency...

  • Nevirapine hastens liver fibrosis in HIV/HCV coinfection.  // Reactions Weekly;6/26/2004, Issue 1007, p6 

    Discusses research being done on the association of nevirapine that contains highly active antiretroviral therapy regimens with liver fibrosis and fibrosis progression in HIV and hepatitis C virus patients. Reference to a study by J. Marcías et al., published in the March 26, 2004 issue of...

  • HAART-Prolonged Life of HIV-Infected Patients Should Not Be Shortened by Hepatitis C. Horster, S.; Goebel, F.D. // Infection;Dec2004, Vol. 32 Issue 6, p369 

    As highly active antiretroviral treatment (HAART) prolongs the life of HIV-infected individuals and reduces mortality associated with opportunistic infections, liver diseases have become a major challenge in the management of these patients. Up to 45% of deaths of persons with HIV are related to...

  • Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients. Pérez-Rodríguez, Ma Teresa; Sopeña, Bernardo; Crespo, Manuel; Rivera, Alberto; del Blanco, Teresa González; Ocampo, Antonio; Martínez-Vázquez, César; Alvaro, Montiel-Jarquín // World Journal of Gastroenterology;3/14/2009, Vol. 15 Issue 10, p1237 

    AIM: To determine the prevalence and clinical relevance of isolated antibodies to hepatitis B core antigen as the only marker of infection ("anti-HBc alone") among human immunodeficiency virus (HIV) type-1 infected patients. Occult hepatitis B infection frequency was also evaluated. METHODS:...

  • Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Ena, Javier; Amador, Concepción; Benito, Concepción; Fenoll, Vicenta; Pasquau, Francisco // International Journal of STD & AIDS;Nov2003, Vol. 14 Issue 11, p776 

    We examined the risk and determinants of developing severe liver toxicity in 108 HIV-infected patients showing adherence to nevirapine- and efavirenz-containing regimens. Between January 1997 and December 2000, 70 patients were treated with nevirapine- and 38 patients with efavirenz-containing...

  • Evidence of Recombination in Intrapatient Populations of Hepatitis C Virus. Sentandreu, Vicente; Jiménez-Hernández, Nuria; Torres-Puente, Manuela; Bracho, María Alma; Valero, Ana; Gosalbes, María José; Ortega, Enrique; Moya, Andrés; González-Candelas, Fernando // PLoS ONE;2008, Vol. 3 Issue 9, p1 

    Hepatitis C virus (HCV) is a major cause of liver disease worldwide and a potential cause of substantial morbidity and mortality in the future. HCV is characterized by a high level of genetic heterogeneity. Although homologous recombination has been demonstrated in many members of the family...

  • HAART and liver: is it safe? Antonello, Vicente Sperb; Kliemann, Dimas Alexandre; Santos, Breno Riegel; Tovo, Cristiane Valle // Journal of Infection in Developing Countries;Nov2014, Vol. 8 Issue 11, p1444 

    Introduction: Liver disease caused by hepatitis C virus (HCV) is a major cause of morbidity in HIV patients. This study investigates the possibility that chronic HCV increases the risk of hepatotoxicity after highly active antiretroviral therapy (HAART) initiation. Methodology: The data from 30...

  • Changing Treatment Paradigms: Hepatitis C Virus in HIV-Infected Patients. Kadam, Jaydeep S.; Talal, Andrew H. // AIDS Patient Care & STDs;Mar2007, Vol. 21 Issue 3, p154 

    The evaluation of hepatic histology and treatment of hepatitis C virus (HCV)/HIV-coinfected patients is rapidly changing. HCV has become an important cause of mortality in HIV-infected patients. Consequently, assessment of liver histology in all coinfected patients is particularly important. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics